ReviewMolecular biomedicine2026
Interleukin-8 in health and disease.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Cytokines are among the main factors involved in indirect cell-to-cell communication in physiological and pathological conditions. In this way, cytokines are soluble and tissue-resident easily detectable biomarkers for the diagnosis and the prediction of clinical outcome, as well as drug targets. Over the years, the pleiotropic IL-8 gained a central role in the pathogenesis of several immunological disorders, spanning from autoimmune pathologies and sepsis to neurological, liver and cardiovascular diseases. In several solid cancers, IL-8 not only serves as a prognostic biomarker but also as predictive tool. Increasing evidence highlighted IL-8 as a prognostic/predictive biomarker even for immunotherapy to stratify eligible patients, to avoid unnecessary toxicity and progression. Today, a comprehensive review covering IL-8 in all these fields has not yet been published. Hence, we aim to provide preclinical and clinical evidence on the biology and functions of IL-8, involved in the pathogenesis of non-malignant diseases, including inflammatory bowel diseases, sepsis, neuroinflammation, liver and cardiovascular pathologies. In oncology area, we will describe the pro-tumorigenic roles, including the characterization of the immunosuppressive microenvironment, also discussing the implications of direct/indirect IL-8 targeting and the involvement of gut microbiota. Unfortunately, the main obstacles to establish IL-8 as a useful non-invasive clinical tool for diagnosis and treatments' selection are the lack of the standardization of method detection and the source of IL-8 production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.